Register or Submit a manuscript.
OBM Neurobiology

(ISSN 2573-4407)

OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Novel Approaches to Glioblastoma

Submission Deadline: November 30, 2020 (Closed) Submit Now

Guest Editor

Divya Mella, MD

Attending Neuro-Oncologist, Baylor Scott and White, Dallas, TX-USA

Website | E-Mail

Research Interests: Neuro-Oncology; Brain Tumors; Neuropathology; Neuroimaging

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Review

Illuminate Resection Pathways with Fluorescence Guidance in Glioma Surgery: Case Reports and Systematic Review

Received: 20 April 2024;  Published: 09 September 2024;  doi: 10.21926/obm.neurobiol.2403244

Abstract

Gliomas are the most common brain tumor in adults, with a poor prognosis despite intensive treatments. Complete surgical resection is difficult due to its infiltrative growth, but aggressive surgery improves outcomes. Fluorescence-guided surgery (FGS) is used to distinguish tumor tissue during surgery. 5-Aminolevulinic Acid (5-ALA) is a crucia [...]
Open Access Review

Minimally Invasive Treatments for Glioblastoma: A Review of Current and Emerging Surgical Technologies

Received: 22 February 2022;  Published: 03 March 2023;  doi: 10.21926/obm.neurobiol.2301160

Abstract

Glioblastoma (GBM) is malignant, primary intracranial neoplasm associated with poor outcomes. Maximal, safe cytoreduction remains an important component of effective treatment for patients with this disease; however, some patients are not candidates for resection due to comorbid status, tumor location, or other factors. In this review, we [...]
Open Access Review

Examining the Role of Specialized DNA Polymerases in the Development of Temozolomide Resistance in Glioblastoma Multiforme

Received: 09 February 2021;  Published: 18 May 2021;  doi: 10.21926/obm.neurobiol.2102096

Abstract

Glioblastoma multiforme (GBM) is an extremely malignant type of primary brain tumor that exhibits a high mortality rate. Current standard therapy involves surgery followed by radiation and treatment with the DNA-alkylating agent, temozolomide (TMZ). While TMZ treatment can extend post-operative survival, most patients develop resis [...]
Open Access Review

Light-Activated Local Drug Delivery From Hydrogels: Potential for GBM Treatment

Received: 15 December 2020;  Published: 23 March 2021;  doi: 10.21926/obm.neurobiol.2101090

Abstract

Following post-operative treatment, the vast majority of GBMs recur, usually within 2 cm of the tumor resection margin. Since these tumors seldom metastasize outside the CNS, improved localized therapies should prove beneficial. Drug delivery systems (DDS) that allow control over drug release by an externally applied energy, such as light [...]
Journal Metrics
2023
CiteScore SJR SNIP
1.00.2320.256
Newsletter
Newsletter  

TOP